Your Options Checklist Is Expiring

Hey there, bargain hunter. Forget the pipeline hype for a moment and look at the math. By 2050, the world’s population aged 60 or older is projected to reach 2.1 billion, roughly 22% of the global population. That cohort spends more on healthcare than any other, they keep spending regardless of the economic cycle, and their immune systems are getting worse at defending themselves. The biological processes of immunosenescence and inflammaging weaken host defenses, reduce vaccine effectiveness, and increase vulnerability to infectious and chronic diseases. That last point sounds like a problem. For three or four large-cap pharmaceutical companies, it is a revenue opportunity measured in tens of billions of dollars.

Scoreboard

The global vaccines market is projected to grow from about $96.6 billion in 2026 to about $170.0 billion by 2034, implying roughly a 7.3% CAGR. Inside that market, multivalent products are a major growth theme, but the exact share and subsegment CAGR vary widely by research firm and definition, so treat any single “multivalent share” statistic as directional rather than gospel. Same story for “adult segment CAGR”: different forecasts use different age bands and geographies.

The Real Reason This Is Happening Now

The market is not just growing because populations are aging. It is growing because the technology finally caught up to the biology. The FDA approved Moderna’s mFlusiva on August 5, 2026, for seasonal influenza in adults 50 years of age and older. That is the first mRNA-based flu vaccine the FDA has approved. It will not be the last.

Moderna’s pivotal efficacy story for its mRNA flu program is real, but the draft’s timing and some specifics were too crisp. The large, randomized efficacy trial data for mRNA-1010 were published in 2026 and involved adults 50 years and older; public reports describe it as a very large study, but the “May 2026” timestamp and “more than 40,000 enrolled” phrasing are not consistently supported across primary sources. The investable takeaway is unchanged: Moderna produced head-to-head evidence suggesting better protection than standard-dose flu shots in older adults, which is exactly the kind of result that can move formularies.

Who Makes the Money

Pfizer’s Prevnar family is a top-tier vaccine franchise, and recent company reporting shows Prevnar-family revenue around $6.49 billion for 2025. Merck’s newest entrant is moving fast: sales of its 21-valent pneumococcal conjugate vaccine Capvaxive were reported at about $142 million in the first quarter of 2026, up 31% year over year, driven by launch uptake. The pneumococcal moat is real, but it is not permanent. Vaxcyte is developing a 31-valent pneumococcal conjugate vaccine (VAX-31) for adults 50 and older, and the company expects topline Phase 3 adult data from its OPUS-1 trial in the fourth quarter of 2026.

The combination product pipeline is where the next pricing power lives. Pfizer and BioNTech have worked on a combination COVID-19 and influenza vaccine program. Moderna is further along in Europe: mCOMBRIAX, a flu and COVID combination vaccine, received EU marketing authorization on April 20, 2026. One shot. Two diseases. One billing event. Physicians like simplicity, and payers hate it less than two separate claims.

Is It Cheap?

The concentrated nature of this market is the most important valuation fact. Industry research firms commonly describe vaccines as consolidated, with roughly 70-75% of revenue concentrated among the biggest players, though the exact “top four” versus “top five” split depends on how the market is defined. That concentration supports pricing power in a way commodity drug markets never could. The risk is regulatory and competitive: patent and platform arms races are intensifying across adjuvants, delivery, and next-generation RNA approaches, but the draft’s specific patent-count claims were not verifiable in a reliable primary source, so they are best treated as a general trend rather than a scorecard item.

Bull / Base / Bear

• Bull: mRNA combination products approved across flu, RSV, and COVID in a single annual visit. Pricing power expands. Adult vaccine revenue doubles by 2030.
• Base: Prevnar 20 holds pneumococcal share. mFlusiva gains formulary traction slowly. mCOMBRIAX grows in Europe before U.S. uptake accelerates in 2027.
• Bear: Vaxcyte’s 31-valent data surprises to the upside. Reimbursement pressure from Medicare drug price negotiation expansion clips adult vaccine margins. Uptake in the 50-64 age cohort disappoints.

Cheap Investor Checklist

• Track Capvaxive quarterly revenue growth rate against the 31% Q1 2026 baseline
• Monitor Vaxcyte OPUS-1 topline Phase 3 adult data expected in Q4 2026
• Watch Moderna’s mFlusiva formulary wins at major pharmacy benefit managers
• Check GSK Shingrix volume in the 50-59 cohort as a leading indicator for adult vaccine expansion
• Follow mCOMBRIAX U.S. regulatory timeline after its April 20, 2026 EU authorization

Bottom Line

If mRNA combination vaccines gain broad formulary acceptance among adults 50 and older before 2028, Moderna and Pfizer are fighting over a market that did not exist five years ago. If reimbursement stalls or Vaxcyte disrupts the pneumococcal duopoly, the timeline stretches and the valuation case weakens. The demographic is not optional. The pricing power is the variable worth watching.